Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

L.A. McKeown

March 12, 2025

News Daily News

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

Michael O'Riordan

January 03, 2024

Presentation TCT 2023

TCT 380: The impact of obesity on antiplatelet monotherapy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial

Presenter: Minju Han

October 25, 2023

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

Presentation TCT 2022

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

Presenter: Jeehoon Kang

September 17, 2022

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

Todd Neale

August 29, 2022

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2021

Shelley Wood

May 31, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

Video

» Interview

HOST-EXAM: Aspirin vs Clopidogrel During Chronic Maintenance Monotherapy After PCI

May 20, 2021

Advertisement

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

Five Years Post-PCI, Clopidogrel Monotherapy Holds Up in STOPDAPT-2

TCT 380: The impact of obesity on antiplatelet monotherapy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

TCT 22: Clopidogrel versus Aspirin in the Chronic Maintenance Period Following Percutaneous Coronary Intervention in Patients with Acute Coronary syndrome: Subgroup Analysis of the HOST-EXAM trial

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

TCTMD’s Top 10 Most Popular Stories for May 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

HOST-EXAM: Aspirin vs Clopidogrel During Chronic Maintenance Monotherapy After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content